429P Real-world (RW) effectiveness and safety of lurbinectedin for previously treated small cell lung cancer (SCLC): Jazz EMERGE 402

Authors

• B Halmos
• P Lammers
• G Liu
• L Shunyakov
• F B. Badin
• S Kassam
• Mehul Patel, Rochester Regional HealthFollow
• Y Ji
• C Labbe
• V Rabara
• M Hashmi
• S Dakhil
• M Weiss
• A Gowan
• N Bouchard
• B Rengarajan
• D Fuller
• N Naveh

Department

Oncology and Hematology

Document Type

Conference Proceeding

Publication Title

ESMO Open

Conference Name

European Lung Cancer Congress (ELCC)

Conference Date

2026-03-25 - 2026-03-28

First Page

12

Last Page

13

DOI

10.1016/j.esmoop.2026.106743

Volume

11

Issue

Supplement 3

Publication Date

4-1-2026

Recommended Citation

Halmos, B., Lammers, P., Liu, G., Shunyakov, L., Badin, F. B., Kassam, S., Patel, M., Ji, Y., Labbe, C., Rabara, V., Hashmi, M., Dakhil, S., Weiss, M., Gowan, A., Bouchard, N., Rengarajan, B., Fuller, D., & Naveh, N. (2026). 429P Real-world (RW) effectiveness and safety of lurbinectedin for previously treated small cell lung cancer (SCLC): Jazz EMERGE 402. ESMO Open, 11 (Supplement 3), 12-13. https://doi.org/10.1016/j.esmoop.2026.106743